Healthcare Shares Soar Following Major Price Target Increase

By: Dylan Sikes – AllPennyStocks.com News

Tuesday, May 14, 2024

Just one session following the company releasing strong Q1 2024 earnings, a California-based healthcare company is finding tremendous success on Tuesday. This comes as no real surprise after Cantor Fitzgerald adjusted the price target from $5 to $7 while maintaining an overweight rating.

It’s no wonder shares of Exagen Inc. (Nasdaq:XGN) rallied strongly throughout Tuesday’s session, with traders pushing shares of the micro cap up to $2.00/share (+21.95%) at the session high. This move is a strong continuation of the success this stock has seen over the last four or so sessions.

Exagen Inc is a commercial-stage diagnostics company committed to addressing the unmet need for the accurate diagnosis and monitoring of patients affected by autoimmune rheumatic diseases. It currently markets ten testing products under its Avise brand to provide an accurate, timely, and differential diagnosis and to optimize the treatment of ARDs. It markets and sells solutions to community rheumatologists.

Copyright © 2024 AllPennyStocks.com. All rights reserved. Republication or redistribution of AllPennyStocks.com's content is expressly prohibited without the prior written consent of AllPennyStocks.com. AllPennyStocks.com shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.